July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Bevacizumab can inhibit histone deacetylase (HDAC) activity in ARPE-19 cells
Author Affiliations & Notes
  • Noor-Ul-Ain Shekoh
    Ophthalmology, University of california Irvine, Irvine, California, United States
  • Mohamed Mohamed
    Ophthalmology, University of california Irvine, Irvine, California, United States
    Department of Ophthalmology, Minia University, Minia, Egypt
  • Sonali Nashine
    Ophthalmology, University of california Irvine, Irvine, California, United States
  • Baruch D Kuppermann
    Ophthalmology, University of california Irvine, Irvine, California, United States
  • Cristina M Kenney
    Ophthalmology, University of california Irvine, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Noor-Ul-Ain Shekoh, None; Mohamed Mohamed, None; Sonali Nashine, None; Baruch Kuppermann, Aerpio (C), Alcon (F), Alcon (C), Alimera (F), Alimera (C), Allegro (F), Allegro (C), Allergan (F), Allergan (C), Apellis (F), Catalyst (C), Cell Care (C), Dose (C), Eyedaptic (C), Genentech (C), Genetech (F), Glaukos (C), GSK (F), Ionis (C), J-cyte (C), J-Cyte (F), Novartis (C), Ophthotech (F), Regeneron (F), ThromboGenics (F); Cristina Kenney, None
  • Footnotes
    Support  Funding supported by Discovery Eye Foundation, Polly and Michael Smith, Iris and B. Gerald Cantor Foundation, Roy and Edith Carver Foundation, Max Factor Family Foundation, and an unrestricted grant from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3986. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Noor-Ul-Ain Shekoh, Mohamed Mohamed, Sonali Nashine, Baruch D Kuppermann, Cristina M Kenney; Bevacizumab can inhibit histone deacetylase (HDAC) activity in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3986. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of choroidal neovascularization and has been the main target for wet AMD therapy. The variability in patients’ response to anti-VEGF therapy has been a major focus of interest. Several clinical, behavioural and genetic factors have been proposed to influence the outcome of anti-VEGF therapy.
Epigenetics is the study of covalent modifications of the genome that alter gene structure and function without changing its sequence. Examples include DNA methylation, along with histone acetylation and deacetylation. Epigenetic mechanisms can explain the impact of gene-environment interactions on different disease phenotypes.
The purpose of this study is to investigate the possible effects of an anti-VEGF drug, bevacizumab, on histone deacetylase (HDAC) activity in ARPE-19 cells.

Methods : ARPE-19 cells were plated for 24 hours, then treated with either bevacizumab at 1X concentration of the clinical intravitreal dose (12.5 μL/mL), or 0.3 μM trichostatin A (an HDAC inhibitor), or a combination of both drugs. Untreated cells were used as controls.
Proteins were extracted using RIPA cell lysis buffer containing a protease inhibitor cocktail. Cell lysates were centrifuged and stored at -80 C until further use.
HDAC activities were measured with a fluorometric HDAC assay kit and a fluorimeter plate reader using the 350 nm excitation and 440 nm emission wavelengths. Fluorescence was quantified in Relative Fluorescence Units (RFU). Unpaired t-test was used for statistical analysis and P value <0.05 was considered significant.

Results : Both bevacizumab (B) and trichostatin A (T) significantly decreased HDAC activities compared to untreated (UNT) cells (P= 0.03 and 0.01, respectively). A combination of both drugs (B+T) significantly inhibited HDAC activity as well (P= 0.02) compared to untreated cultures, but a synergistic effect could not be demonstrated (Figure 1).

Conclusions : Our results show that bevacizumab can inhibit HDAC activity in ARPE-19 cells. This, in turn, indicates that anti-VEGF drugs may alter the acetylation status in the retina. This is important because it suggests that the so called drug “resistance” may be in part due to the treatment interaction with different “epigenome” profiles that occur in different patients.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×